Chronic Lymphocytic Leukemia | Clinical

Liso-Cel Achieves High MRD Negativity Rate in High-Risk CLL/SLL

December 08, 2020

Chimeric antigen receptor T-cell therapy with lisocabtagene maraleucel led to rapid and durable responses in patients with high-risk relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Umbralisib/Ublituximab Plus Venetoclax Induces High Objective Response Rate in Relapsed/Refractory CLL

December 07, 2020

The combination of umbralisib plus ublituximab plus venetoclax demonstrated encouraging efficacy as treatment of patients with relapsed/refractory chronic lymphocytic leukemia, including those who are refractory to prior therapy with a Bruton tyrosine kinase inhibitor.

Ublituximab Doublet Bests Chemoimmunotherapy in Chronic Lymphocytic Leukemia

December 07, 2020

In the phase 3 UNITY-CLL study, ublituximab in combination with umbralisib demonstrated synergistic activity in patients with chronic lymphocytic leukemia compared with standard of care chemoimmunotherapy irrespective of prior treatment.

Pooled Analysis Supports Use of Acalabrutinib in Patients With Chronic Lymphocytic Leukemia

December 07, 2020

Jennifer R. Brown, MD, PhD, discusses the implications of the findings from a pooled analysis of cardiovascular events from studies of the next-generation BTK inhibitor acalabrutinib monotherapy as treatment of patients with chronic lymphocytic leukemia.

Venetoclax/Rituximab Shows 5-Year Survival Benefit in Relapsed/Refractory CLL

December 05, 2020

Sustained progression-free survival and overall survival benefit at 5 years were observed in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia treated with the combination of venetoclax plus rituximab compared with bendamustine plus rituximab in the MURANO trial.

Similar 1-Year DFS Observed With Continued Ibrutinib, Following Fixed-Duration of Ibrutinib/Venetoclax Vs Placebo in CLL/SLL

December 05, 2020

Placebo following a fixed-treatment duration of ibrutinib combined with venetoclax achieved similar 1-year disease-free survival results compared with patients who remained on ibrutinib following confirmed undetectable minimal residual disease in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.